Gregory D. Frank is director of business development and marketing in the Biosciences Division at SRI International. In this role, his responsibilities include drug licensing, business development, and marketing services to commercial partners and clients. He also manages the government proposal process for SRI’s Biosciences Division.

Previously, Frank was global business development manager at Pharsight Corporation. Prior to that, he was director of business development and part of the start-up team at Metazoa, which was acquired by Pharsight.

Frank has broad experience in the pharmaceutical industry, including basic research, drug discovery and development, licensing, market research, business development, marketing, and sales.

He has published a number of research papers and is author on one U.S. patent.

Frank received his Ph.D. in immunology from Stanford University, and his B.A. in biology from the University of California at Santa Cruz.